Home/AtriCure/Justin J. Noznesky
JJ

Justin J. Noznesky

Chief Strategy & Corporate Development Officer

AtriCure

AtriCure Pipeline

DrugIndicationPhase
BoxX-NoAF Clinical TrialPrevention of new-onset post-operative atrial fibrillationPivotal Trial
Hybrid AF Therapy (EPi-Sense)Symptomatic Persistent & Long-Standing Persistent Atrial FibrillationCommercial
Cryo Nerve Block ExpansionPain management for new surgical indications (e.g., abdominal, orthopedic)R&D